Benjamin P. Saylor

Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.


FDA grants fast track designation for oral mCRPC agent

September 16, 2020

The FDA has granted fast track designation to EPI-7386, an oral, highly selective N-terminal domain inhibitor of the androgen receptor for treatment of mCRPC resistant to standard-of-care treatment.

FDA approves additional recommended dosage for anti-PD-1 therapy

May 13, 2020

The FDA approved an additional recommended dosage of 400 mg every 6 weeks for the anti-PD-1 therapy pembrolizumab (Keytruda), across all adult indications, including monotherapy and combination therapy, Merck reported.